When ADC Meets PROTAC, What Spark Will Fly?
Time：
2026-02-02 08:16
Author：
xieyijun
Hengrui's "Pathfinding" in Multinational Corporations (MNCs)
The spotlight has not yet arrived.
Time：
2026-01-31 08:30
Author：
xieyijun
Find the β for the innovative drug industry in 2026
Time：
2026-01-30 09:35
Author：
xieyijun
JPM 2026 Ultimate Review: Watershed, New Reality and New Venture
Distinguish reality from hype, and trends from fluctuations
Time：
2026-01-29 08:58
Author：
xieyijun
Time：
2026-01-27 08:56
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务